Figure 4 Precision prescribing

Slides:

Advertisements

Similar presentations

Nat. Rev. Cardiol. doi: /nrcardio

Advertisements

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Does One Size Fit All in Obesity Management?

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 2 Binding properties of P2Y12-receptor inhibitors

Figure 5 BMI and cardiorespiratory fitness levels

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Two approaches to therapeutic genome editing

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 2 Three-year survival rates on the basis of body composition

Figure 2 Physical activity and obesity levels by WHO-designated region and sex Figure 2 | Physical activity and obesity levels by WHO-designated region.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Proactive and reactive prevention of cardiovascular disease

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Drug cycling with collateral sensitivity

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Examples of biomarker-guided trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Milestones in coronary angioplasty

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

Figure 1 Essential features and goals of a precision medicine system

Classification of statins/dosages according to the attainable

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Enrichment strategies for clinical trials

Figure 2 Precision medicine — describing individuals

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Determination of the primary site

Presentation transcript:

Figure 4 Precision prescribing Figure 4 | Precision prescribing. In the precision medicine era, the precision patient descriptor serves as the set of predictive factors (such as sex, age, and weight) to identify a pharmacological regimen that is likely to be associated with maximum benefit and minimal risk for a given individual on the basis of the principles originally described in 1997 by Sheiner71. Modified from Sheiner, L. B. The intellectual health of clinical drug evaluation. Clin. Pharmacol. Ther. 50, 4–9 (1991), with permission from Wiley. Modified from Sheiner, L. B. The intellectual health of clinical drug evaluation. Clin. Pharmacol. Ther. 50, 4–9 (1991), with permission from Wiley Antman, E. M. & Loscalzo, J. (2016) Precision medicine in cardiology Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.101